Cannabis Shows Promise for Managing Symptoms in Advanced Kidney Disease

Patients with advanced kidney disease experience significant symptoms that are often undertreated, and preliminary evidence suggests cannabinoids could help with pain, nausea, appetite loss, and itching.

Rein, Joshua L et al.·American journal of kidney diseases : the official journal of the National Kidney Foundation·2018·Preliminary EvidenceNarrative Review
RTHC-01809Narrative ReviewPreliminary Evidence2018RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Narrative Review
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

The review found emerging evidence supporting potential benefits of medical marijuana for four common symptoms in advanced CKD and dialysis patients: chronic pain, nausea/vomiting, anorexia/cachexia, and pruritus (itching). The endocannabinoid system appears to play a role in kidney function and disease.

Key Numbers

29 US states had medical marijuana programs at time of publication. CKD/ESRD patients experience chronic pain, nausea, appetite loss, and itching at rates far exceeding the general population.

How They Did This

Narrative review of available evidence on medical marijuana use for symptom management in chronic kidney disease and end-stage renal disease.

Why This Research Matters

Patients on dialysis often suffer from symptoms that are difficult to treat with conventional medications due to altered drug metabolism and increased side effect risk. Cannabinoids represent a potential alternative, especially as legal access expands.

The Bigger Picture

As more patients with kidney disease live longer on dialysis, symptom management becomes increasingly important for quality of life. Cannabinoids could fill a therapeutic gap, but the altered pharmacokinetics in kidney disease make careful research essential.

What This Study Doesn't Tell Us

Narrative review based on limited direct evidence in CKD/ESRD populations. Most cannabinoid research has been in other patient populations. No clinical trials specific to kidney disease patients were available.

Questions This Raises

  • ?How is cannabinoid metabolism affected by impaired kidney function?
  • ?Are there specific dosing considerations for dialysis patients?
  • ?Could cannabinoids interact with common medications used in CKD?

Trust & Context

Key Stat:
Four common symptoms in advanced kidney disease - pain, nausea, appetite loss, and itching - may respond to cannabinoid treatment based on evidence from other populations.
Evidence Grade:
Preliminary - narrative review largely extrapolating from non-kidney-disease populations with limited direct evidence.
Study Age:
Published in 2018. Cannabis research in kidney disease remains an emerging field.
Original Title:
Marijuana and Cannabinoids in ESRD and Earlier Stages of CKD.
Published In:
American journal of kidney diseases : the official journal of the National Kidney Foundation, 71(2), 267-274 (2018)
Database ID:
RTHC-01809

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research without a strict systematic method.

What do these levels mean? →

Frequently Asked Questions

Can cannabis help with kidney disease symptoms?

This review found preliminary evidence that cannabinoids could help with pain, nausea, appetite loss, and itching - common problems in advanced kidney disease. However, most evidence comes from other patient populations, and kidney disease may affect how the body processes cannabinoids.

Is cannabis safe for people on dialysis?

The review notes that impaired kidney function alters drug metabolism, and specific safety data for cannabinoids in dialysis patients is lacking. Research into the kidney's own endocannabinoid system is still in early stages.

Read More on RethinkTHC

Cite This Study

RTHC-01809·https://rethinkthc.com/research/RTHC-01809

APA

Rein, Joshua L; Wyatt, Christina M. (2018). Marijuana and Cannabinoids in ESRD and Earlier Stages of CKD.. American journal of kidney diseases : the official journal of the National Kidney Foundation, 71(2), 267-274. https://doi.org/10.1053/j.ajkd.2017.06.020

MLA

Rein, Joshua L, et al. "Marijuana and Cannabinoids in ESRD and Earlier Stages of CKD.." American journal of kidney diseases : the official journal of the National Kidney Foundation, 2018. https://doi.org/10.1053/j.ajkd.2017.06.020

RethinkTHC

RethinkTHC Research Database. "Marijuana and Cannabinoids in ESRD and Earlier Stages of CKD..." RTHC-01809. Retrieved from https://rethinkthc.com/research/rein-2018-marijuana-and-cannabinoids-in

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.